Clinical Trial Update: Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating naive HBI0101 CAR-T therapy in relapsed/refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• HBI0101 CAR-T therapy (HBI0101 CAR-T)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Relapsed/Refractory Multiple Myeloma (MM) | Phase 1 | Status: RECRUITING